AUS
NZ
UK
CA
USA
IND
Investors are reacting strongly to the latest quarterly results and trial findings, causing the Telix Pharmaceuticals Ltd (ASX: TLX) share price to tumble by 12% in afternoon trade, down to $9.04 per share. This decline is having a notable impact on the healthcare sector, which is currently among the day's underperformers in the market.
Telix released its third-quarter results after the market closed yesterday, and today's market reaction may be influenced by the information shared on Wednesday.
A Positive Quarterly Performance
Despite the sharp decline in the Telix Pharmaceuticals share price, the company's third-quarter results were actually quite promising. Over the three months ending on September 30, Telix experienced continued growth, primarily driven by its Illuccix injection.
The Illuccix injection is used as a radioactive diagnostic indicator for PET scans in prostate cancer. The report indicates that dose volumes continue to rise, with US sales increasing by 13% compared to the previous quarter, reaching A$130.6 million. The company not only attracted new customers but also retained and grew existing accounts.
Notably, there was a shift in the company's revenue mix, with a 26% government and 74% commercial weighting compared to the previous corresponding period's 19% government and 81% commercial weighting.
Total revenue for the quarter reached A$133.6 million, marking a significant 134% increase from the same period last year. Dr. Christian Behrenbruch, Telix's Managing Director and CEO, expressed his satisfaction, stating:
"We have posted another quarter of double-digit revenue growth for Illuccix in the US with average daily demand for doses continuing to grow month-on-month."
He also highlighted the company's upcoming value drivers, including the commencement of the ProstACT GLOBAL study and the progress in the US regulatory filing and commercial launch preparations for renal (kidney) and brain cancer imaging agents.
The growth in dose volume during the third quarter was achieved while maintaining positive cash flow, marking the fourth consecutive quarter of this accomplishment. One might expect this to boost the Telix Pharmaceuticals share price.
The net operating cash flows doubled from the previous quarter, reaching $21.4 million. As a result, the company ended the period with a cash balance of $137.4 million.
Factors Behind the Share Price Decline
Given the largely positive Q3 results, investors might wonder why the Telix Pharmaceuticals share price is declining. While it's challenging to pinpoint the exact cause, part of the market's skepticism may arise from the preliminary results of Telix's phase I ProstACT SELECT study.
The study was successful in achieving its primary objectives, demonstrating the safety and tolerability of two doses of TLX591 administered two weeks apart. Additionally, the study indicated a significant reduction in prostate-specific antigen.
However, the findings noted grade 3 and 4 hematologic events. Grade 3 is categorized as severe or medically significant but not immediately life-threatening, while grade 4 is considered life-threatening, requiring urgent intervention. Telix clarified that these hematologic events were transient and reversible.
This might explain the downward pressure on the Telix Pharmaceuticals share price today.
